Immunogen (IMGN) reported Q4 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $41.17 million versus the consensus estimate of $17.43 million.
Immunogen (IMGN) reported Q4 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $41.17 million versus the consensus estimate of $17.43 million.